You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 2.2% | 2.4% |
| Div Cover | 2.6 | 2.8 |
| Op Mrgn | 18.5% | 30.0% |
| ROCE | 60.7% |
| Latest | Forecast | |
|---|---|---|
| P/E | 16.9 | 0.0 |
| PEG | 1.3 | 1.6 |
| Price / Revenue | 4.0 | 2.8 |
| Price / Book value | 5.3 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 18.0% | 0.0% |
| PBT | 26.0% | n/a |
| EPS | 13.1% | 0.0% |
| DPS | 6.9% | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | 26,617.00 | 3,916.00 | $2.44 | 41.0 | 0.3 | 137% | $2.80 | 2.8% |
| 2021-12-31 | 37,417.00 | -265.00 | $0.08 | 1,467.0 | -15.2 | -97% | $2.87 | 2.4% |
| 2022-12-31 | 44,351.00 | 2,501.00 | $2.12 | 64.0 | 0.0 | 2,550% | $2.90 | 2.1% |
| 2023-12-31 | 45,811.00 | 6,899.00 | $7.26 | 18.6 | 0.1 | 242% | $2.90 | 2.1% |
| 2024-12-31 | 54,073.00 | 8,691.00 | $8.21 | 16.0 | 1.2 | 13% | $3.10 | 2.4% |
| AstraZeneca receives positive Phase III trial results from Enhertu study Sharecast News | 22 Apr |
|---|---|
| London close: Stocks fall as China retaliates to latest US tariffs Sharecast News | 09 Apr |
| AstraZeneca's Enhertu gets further EU approval Sharecast News | 04 Apr |
| Enhertu combination improved PFS in 1L HER2+ mBC | 22-Apr-25 07:02 |
|---|---|
| Result of AGM | 11-Apr-25 17:30 |
| Imfinzi approved in EU for AEGEAN | 04-Apr-25 07:05 |
| Enhertu approved in EU in post-ET breast cancer | 04-Apr-25 07:01 |
| Total Voting Rights | 01-Apr-25 15:00 |